tert-butyl 5-chloro-2-(diethoxyphosphoryl)valerate | 870843-25-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: tert-butyl 5-chloro-2-(diethoxyphosphoryl)valerate
• 英文别名: 5-chloro-2-(diethoxyphosphoryl)valeric acid tert-butyl ester；tert-butyl 5-chloro-2-(diethoxyphosphoryl)pentanoate；Tert-butyl 5-chloro-2-(diethoxyphosphoryl)valerate；tert-butyl 5-chloro-2-diethoxyphosphorylpentanoate
• CAS: 870843-25-7
• 化学式: C₁₃H₂₆ClO₅P
• 分子量: 328.773
• InChiKey: DZDINQRIIOTRRL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  20
• 可旋转键数：
  11
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  61.8
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  tert-butyl 5-chloro-2-(diethoxyphosphoryl)valerate 在 三丁基膦 、 四磷十氧化物 、 sodium methylate 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三氟乙酸 、 lithium hydroxide 、 肼 、 1,1'-azodicarbonyl-dipiperidine 作用下， 以 四氢呋喃 、 甲醇 、 乙醇 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 生成 (5R,10E)-10-[[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]methylidene]-5-(3,4,5-trifluorophenyl)-3,4,5,7,8,9-hexahydropyrido[2,1-c][1,2,4]oxadiazepine
  参考文献：
  名称：

  融合的草二氮杂卓作为γ分泌酶调节剂治疗阿尔茨海默氏病的发现

  摘要：

  为了进一步改善oxadiazine系列GSM的总体特性，特别是hERG活性，核心结构的构象修饰导致鉴定了融合的草二氮杂卓类化合物，例如7i，其具有改善的hERG抑制特性，并且是高度有效的GSM。大鼠体内和体外。这些SAR探索提供了机会来确定治疗阿尔茨海默氏病的潜在药物。

  DOI：

  10.1016/j.bmcl.2012.11.055
• 作为产物：
  描述：

  1-溴-3-氯丙烷 、 在 sodium hydride 作用下， 以 四氢呋喃 为溶剂， 反应 1.5h， 生成 tert-butyl 5-chloro-2-(diethoxyphosphoryl)valerate
  参考文献：
  名称：

  Synthesis and SAR Studies of Fused Oxadiazines as γ-Secretase Modulators for Treatment of Alzheimer's Disease

  摘要：

  Fused oxadiazines (3) were discovered as selective and orally bioavailable gamma-secretase modulators (GSMs) based on the structural framework of oxadiazoline GSMs. Although structurally related, initial modifications showed that structure-activity relationships (SARs) did not translate from the oxadiazoline to the oxadiazine series. Subsequent SAR studies on modifications at the C3 and C4 positions of the fused oxadiazine core helped to identify GSMs such as compounds 8r and 8s that were highly efficacious in vitro and in vivo in a number of animal models with highly desirable physical and pharmacological properties. Further improvements of in vitro activity and selectivity were achieved by the preparation of fused morpholine oxadiazines. The shift in specificity of APP cleavage rather than a reduction in overall gamma-secretase activity and the lack of changes in substrate accumulation and Notch processing as observed in the animal studies of compound 8s confirm that the oxadiazine series of compounds are potent GSMs.

  DOI：

  10.1021/ml300209g

文献信息

• Synthesis of the γ-Secretase Modulator MK-8428
  作者：Steven P. Miller、William J. Morris、Robert K. Orr、Jeffrey Eckert、Jay Milan、Mathew Maust、Cameron Cowden、Jian Cui

  DOI：10.1021/acs.joc.6b02979

  日期：2017.3.17

  The synthesis of the γ-secretase modulator MK-8428 (1) is described. The synthesis is highlighted by an enzyme-catalyzed reaction to access 3,4,5-trifluoro-(S)-phenylglycine, a 1-pot activation/displacement/deprotection sequence to introduce the aminooxy functionality and a dehydrative intramolecular cyclization under mild conditions to form the oxadiazine heterocycle of 1. In situ reaction monitoring

  描述了γ-分泌酶调节剂MK-8428（1）的合成。通过酶催化反应获得3,4,5-三氟-（S）-苯基甘氨酸，1罐活化/置换/去保护序列以引入氨氧基官能团和在温和条件下脱水脱水分子内环化反应来突出合成形成1的恶二嗪杂环。采用原位反应监测来了解水在1罐活化/置换/去保护序列中形成甲磺酸酯期间的有害作用。
• [EN] GAMMA SECRETASE MODULATORS<br/>[FR] MODULATEURS DE GAMMA SÉCRÉTASE
  申请人：SCHERING CORP

  公开号：WO2010056849A1

  公开（公告）日：2010-05-20

  In its many embodiments, the present invention provides a novel class of heterocyclic compounds of Group A or Group, as defined herein, as modulators of gamma secretase, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the central nervous system using such compounds or pharmaceutical compositions.

  在其多种实施方式中，本发明提供了一类新型的杂环化合物，属于A组或B组，如本文所定义，作为γ-分泌酶调节剂，以及制备这类化合物的方法，含有一种或多种这类化合物的药物组合物，制备含有一种或多种这类化合物的药物配方的方法，以及利用这类化合物或药物组合物治疗、预防、抑制或改善与中枢神经系统相关的一种或多种疾病的方法。
• MULTI-CYCLIC COMPOUNDS
  申请人：KIMURA Teiji

  公开号：US20090062529A1

  公开（公告）日：2009-03-05

  A compound represented by the formula (I): or a pharmacologically acceptable salt thereof, wherein Ar 1 represents an imidazolyl group or the like which may be substituted with a C1-6 alkyl group, Ar 2 represents a phenyl group or the like which may be substituted with a C1-6 alkoxy group, X 1 represents a double bond or the like and Het represents a triazolyl group or the like which may be substituted with a C1-6 alkyl group or the like, is effective as a therapeutic or prophylactic agent for a disease caused by Aβ.

  一种由化学式(I)表示的化合物或其药理学可接受的盐，其中Ar1代表可用C1-6烷基基团取代的咪唑基团或类似基团，Ar2代表可用C1-6烷氧基团取代的苯基团或类似基团，X1代表双键或类似基团，Het代表可用C1-6烷基基团或类似基团取代的三唑基团或类似基团，对由Aβ引起的疾病具有治疗或预防作用。
• Multi-cyclic cinnamide derivatives
  申请人：Kimura Teiji

  公开号：US20070219181A1

  公开（公告）日：2007-09-20

  The present invention provides a compound represented by the formula (I): or a pharmacologically acceptable salt thereof, wherein Ar 1 represents an imidazolyl group that may be substituted with a C1-6 alkyl group, or the like, Ar 2 represents a phenyl group that may be substituted with a C1-6 alkoxy group, or the like, X 1 represents a double bond or the like, and Het represents an imidazolyl group that may be substituted with a C1-6 alkyl group, or the like, which is effective as a therapeutic or prophylactic agent for a disease caused by Aβ.

  本发明提供了一种由以下公式（I）表示的化合物或其药理学上可接受的盐，其中Ar1代表可能用C1-6烷基等取代的咪唑基团，Ar2代表可能用C1-6烷氧基等取代的苯基团，X1代表双键等，Het代表可能用C1-6烷基等取代的咪唑基团，该化合物对由Aβ引起的疾病具有治疗或预防作用。
• Morpholine type cinnamide compound
  申请人：Kimura Teiji

  公开号：US20070117798A1

  公开（公告）日：2007-05-24

  The present invention relates to a compound represented by the formula (I): or a pharmacologically acceptable salt thereof, wherein R 1 , R 2 , R 3 , and R 4 are the same or different and each represent a hydrogen atom or a C1-6 alkyl group; X 1 represents a C1-6 alkylene group that may be substituted; X a represents a methoxy group or a fluorine atom; X b represents an oxygen atom or a methylene group, provided that X b is only an oxygen atom when X a is a methoxy group; and Ar 1 represents an aryl group, pyridinyl group, aryloxy group, or pyridinyloxy group that may have a substituent such as a halogen atom; and to use of the compound or salt as a pharmaceutical agent.

  本发明涉及一种由式(I)表示的化合物或其药理学上可接受的盐，其中R1、R2、R3和R4相同或不同，并且每个代表氢原子或C1-6烷基基团；X1代表可能被取代的C1-6烷基基团；Xa代表甲氧基团或氟原子；Xb代表氧原子或亚甲基基团，前提是当Xa为甲氧基团时，Xb仅为氧原子；Ar1代表可能具有卤素原子等取代基的芳基、吡啶基、芳氧基或吡啶氧基；以及将该化合物或盐用作药物剂的用途。